tuparstobart

Tuparstobart is an investigational monoclonal antibody that targets lymphocyte activation gene 3 (LAG-3, also known as CD223), acting as a checkpoint inhibitor in cancer immunotherapy. It blocks the binding of LAG-3 to its MHC class II ligand, thereby enhancing T cell activation and anti-tumor immune responses. Tuparstobart is being developed primarily for the treatment of various solid tumors, including endometrial cancer, squamous cell carcinoma (notably head and neck), melanoma, Merkel cell carcinoma, transitional cell carcinoma (urothelial), and other advanced malignancies. The drug is administered intravenously and was developed using retrocyte display technology. Its mechanism includes antagonism of LAG-3 to relieve immune suppression in the tumor microenvironment[2][4][5]. Developers include Agenus, Incyte Corporation, and University of Washington.

Brand names

tuparstobart

Other names

Anti-LAG-3 Monoclonal AntibodyAnti-LAG3 Monoclonal AntibodyAnti-LAG 3 Monoclonal Antibody